These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27553740)

  • 1. In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
    García AB; Candel FJ; López L; Chiarella F; Viñuela-Prieto JM
    J Med Microbiol; 2016 Oct; 65(10):1119-1122. PubMed ID: 27553740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Davis KP; McDermott LA; Snydman DR; Aldridge BB
    Microbiol Spectr; 2024 Aug; 12(8):e0097624. PubMed ID: 38916355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.
    Rolston KVI; Jamal M; Nesher L; Raad I; Rice SA; Rybak MJ; Prince RA
    J Glob Antimicrob Resist; 2019 Jun; 17():16-18. PubMed ID: 30844496
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
    Saravolatz LD; Pawlak J
    J Antimicrob Chemother; 2022 Dec; 78(1):238-241. PubMed ID: 36374572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftaroline in combination with other antimicrobials active against Staphylococcus spp.
    Gil Romero Y; Gómez-Garcés JL
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Jan; 38(1):25-27. PubMed ID: 31072712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
    Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
    J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.
    Luther MK; LaPlante KL
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7790-4. PubMed ID: 26369963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.
    Fang H; Fröding I; Gian B; Hæggman S; Tollström UB; Ullberg M; Nord CE
    J Glob Antimicrob Resist; 2016 Jun; 5():31-5. PubMed ID: 27436463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus.
    Hutton MA; Sundaram A; Perri MB; Zervos MJ; Herc ES
    Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115126. PubMed ID: 32861155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
    Barber KE; Rybak MJ; Sakoulas G
    J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
    [No Abstract]   [Full Text] [Related]  

  • 17. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
    Marconescu P; Graviss EA; Musher DM
    Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus.
    Tsai CE; Yang CJ; Chuang YC; Wang JT; Sheng WH; Chen YC; Chang SC
    Int J Infect Dis; 2022 Sep; 122():230-236. PubMed ID: 35640827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.
    Holubar M; Meng L; Alegria W; Deresinski S
    Infect Dis Clin North Am; 2020 Dec; 34(4):849-861. PubMed ID: 33011050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.
    Albac S; Labrousse D; Hayez D; Anzala N; Bonnot D; Chavanet P; Aslangul E; Croisier D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.